CSIMarket
 
Bionik Laboratories Corp   (BNKL)
Other Ticker:  
 
 
Price: $0.1000 $-0.14 -58.333%
Day's High: $0.1 Week Perf: -60 %
Day's Low: $ 0.10 30 Day Perf: -80.56 %
Volume (M): 2 52 Wk High: $ 0.99
Volume (M$): $ 0 52 Wk Avg: $0.42
Open: $0.10 52 Wk Low: $0.10



 Market Capitalization (Millions $) 1
 Shares Outstanding (Millions) 7
 Employees -
 Revenues (TTM) (Millions $) 2
 Net Income (TTM) (Millions $) -5
 Cash Flow (TTM) (Millions $) -2
 Capital Exp. (TTM) (Millions $) 0

Bionik Laboratories Corp
Bionik Laboratories Corp is a medical device and robotics company focused on the development and commercialization of innovative technologies in the healthcare industry. The company specializes in the field of bionics, which involves the application of biological methods and systems to the design of artificial technology. Bionik Laboratories Corp aims to enhance the lives of individuals with physical disabilities by creating advanced robotic systems and rehabilitative solutions. These technologies help improve mobility and rehabilitation outcomes for patients, enabling them to regain independence and improve their quality of life.


   Company Address: 80 Coolidge Hill Road Watertown 2472 MA
   Company Phone Number: 926-4800   Stock Exchange / Ticker: BNKL
   


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Bionik Laboratories Corp

Bionik Laboratories Corp Discloses Q4 2023 Financial Discrepancy: Impressive Hike in Revenue Amidst Negative Return Expansion to $-0.17

Bionik Laboratories Corp, a biotechnology and pharmaceuticals company, recently announced a significant improvement in revenue in the financial fourth quarter of 2023. Despite this positive development, the company posted a loss per stock of $-0.17, higher than the loss of $-0.16 per share in the previous reporting period. Additionally, revenue deteriorated by -12.858% from $0.58 million.
During the fourth quarter of 2023, Bionik Laboratories Corp reported a net loss of $-1.356 million, instead of breaking even as it did in the corresponding period the previous year. Moreover, the company noted a net deficit of $-4.95 million for the entire financial year of 2023, with revenue reaching $1.81 million.






 

Bionik Laboratories's Segments
 
 
• View Complete Report




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com